Joel Wallace

1.0k total citations
18 papers, 803 citations indexed

About

Joel Wallace is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and General Health Professions. According to data from OpenAlex, Joel Wallace has authored 18 papers receiving a total of 803 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in General Health Professions. Recurrent topics in Joel Wallace's work include Renal cell carcinoma treatment (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Erythropoietin and Anemia Treatment (4 papers). Joel Wallace is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Erythropoietin and Anemia Treatment (4 papers). Joel Wallace collaborates with scholars based in United States, France and Spain. Joel Wallace's co-authors include Chiun‐Fang Chiou, Jeff Borenstein, James M. Henning, Joshua J. Ofman, Peter J. Neumann, Joel W. Hay, Hsing-Ting Yu, Emmett B. Keeler, Bernard S. Bloom and Scott Weingarten and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Joel Wallace

17 papers receiving 762 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel Wallace United States 10 254 157 138 128 116 18 803
Lincy S. Lal United States 17 178 0.7× 95 0.6× 77 0.6× 124 1.0× 91 0.8× 98 1.1k
Steven Soroka Canada 17 295 1.2× 192 1.2× 310 2.2× 125 1.0× 113 1.0× 50 1.4k
Sang Mee Lee United States 16 119 0.5× 244 1.6× 75 0.5× 126 1.0× 113 1.0× 50 880
June M. McKoy United States 18 140 0.6× 209 1.3× 82 0.6× 150 1.2× 68 0.6× 60 1.0k
Chris Skedgel Canada 21 319 1.3× 128 0.8× 60 0.4× 88 0.7× 54 0.5× 76 1.3k
Karl Matuszewski United States 15 104 0.4× 68 0.4× 124 0.9× 58 0.5× 77 0.7× 34 809
Marco Barbieri United Kingdom 14 524 2.1× 247 1.6× 64 0.5× 69 0.5× 84 0.7× 34 1.1k
James D. Chambers United States 22 671 2.6× 205 1.3× 62 0.4× 83 0.6× 148 1.3× 90 1.2k
Clark DuMontier United States 16 156 0.6× 81 0.5× 80 0.6× 141 1.1× 50 0.4× 62 890
Sylvain Clauser France 12 162 0.6× 148 0.9× 89 0.6× 186 1.5× 166 1.4× 22 1.0k

Countries citing papers authored by Joel Wallace

Since Specialization
Citations

This map shows the geographic impact of Joel Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Wallace more than expected).

Fields of papers citing papers by Joel Wallace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Wallace. The network helps show where Joel Wallace may publish in the future.

Co-authorship network of co-authors of Joel Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Wallace. A scholar is included among the top collaborators of Joel Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Wallace. Joel Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
Cella, David, Robert J. Motzer, Steven I. Blum, et al.. (2022). Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.. Journal of Clinical Oncology. 40(6_suppl). 323–323. 1 indexed citations
4.
Marteau, Florence, B. Harrow, Christine McCarthy, et al.. (2021). Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 39(6_suppl). 293–293. 6 indexed citations
5.
Marteau, Florence, B. Harrow, Christine McCarthy, et al.. (2021). Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.. Journal of Clinical Oncology. 39(15_suppl). e16539–e16539. 1 indexed citations
6.
Kabbinavar, Fairooz F., Joel Wallace, Eric Holmgren, et al.. (2008). Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. The Oncologist. 13(9). 1021–1029. 37 indexed citations
7.
Nordyke, Robert J., et al.. (2006). Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An. Health and Quality of Life Outcomes. 4(1). 28–28. 9 indexed citations
8.
Mun, Yong, et al.. (2006). Advances in conducting retrospective chart review studies: use of electronic report forms and database in a community study in anemic patients with myelodysplastic syndrome.. PubMed. 3(6 Suppl 4). 12–3. 2 indexed citations
9.
Patton, Jeffrey, et al.. (2006). A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.. PubMed. 3(6). 419–26. 13 indexed citations
10.
Schwartzberg, Lee S., Lorrin Yee, Frank M. Senecal, et al.. (2004). A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer. The Oncologist. 9(6). 696–707. 80 indexed citations
11.
Patton, Jeffrey, Timothy Reeves, & Joel Wallace. (2004). Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice. The Oncologist. 9(4). 451–458. 42 indexed citations
12.
13.
Chiou, Chiun‐Fang, Joel W. Hay, Joel Wallace, et al.. (2003). Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care. 41(1). 32–44. 248 indexed citations
14.
Chiou, Chiun‐Fang, James Trussell, Eileen Reyes, et al.. (2003). Economic analysis of contraceptives for women. Contraception. 68(1). 3–10. 89 indexed citations
15.
Borenstein, Jeff, Emmanuel Saltiel, Joel Wallace, et al.. (2003). Physician‐Pharmacist Comanagement of Hypertension: A Randomized, Comparative Trial. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(2). 209–216. 163 indexed citations
16.
Ofman, Joshua J., Joel Wallace, Enkhe Badamgarav, et al.. (2002). The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage. The American Journal of Gastroenterology. 97(8). 1941–1950. 18 indexed citations
17.
Wallace, Joel, Scott Weingarten, Chiun‐Fang Chiou, et al.. (2002). The limited incorporation of economic analyses in clinical practice guidelines. Journal of General Internal Medicine. 17(3). 210–220. 25 indexed citations
18.
Brophy, Donald F., Joel Wallace, Daniel Kennedy, Todd W.B. Gehr, & David A. Holdford. (2000). Cost‐Effectiveness of Sevelamer versus Calcium Carbonate plus Atorvastatin to Reduce LDL in Patients with Chronic Renal Insufficiency with Dyslipidemia and Hyperphosphatemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(8). 950–957. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lincy S. Lal Breakdown of academic impact, for papers by Steven Soroka Breakdown of academic impact, for papers by Sang Mee Lee Breakdown of academic impact, for papers by June M. McKoy Breakdown of academic impact, for papers by Chris Skedgel Breakdown of academic impact, for papers by Karl Matuszewski Breakdown of academic impact, for papers by Marco Barbieri Breakdown of academic impact, for papers by James D. Chambers Breakdown of academic impact, for papers by Clark DuMontier Breakdown of academic impact, for papers by Sylvain Clauser
Rankless by CCL
2026